Skip to main content
SpringerLink
Log in

Multiple drug resistance and intermediate filaments

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Summary

One major obstacle to the successful treatment of epithelial derived tumors, such as breast and prostate carcinoma, is the presence of a multiple drug resistance phenotype. The drug resistance which is observed in growing epithelial derived cancer cells could either be an intrinsic, selected and/or an acquired characteristic. A survey of the survival data from several laboratories suggests that epithelial derived tumor cells, which have never been challenged with damaging agents, are in some cases 10 to 2,000 times more resistant to various chemotherapeutic agents as compared to hematopoietic cell lines. An intrinsic characteristic of epithelial cells is their resistance to the lethal effects of multiple types of damaging agents. A major feature of epithelial derived tumors is the expression of the intermediate filament type proteins known as cytokeratin. The simplest cytokeratin combination, cytokeratin 8 and 18, is a major cytoplasmic element within the cells of epithelial derived tumors. Earlier work showed that cytokeratin could be modified by mitoxantrone, a chemotherapeutic agent used in the treatment of breast cancer. Increasing data indicates that the intrinsic drug resistance phenotype is due in part to the presence of continued expression of the cytokeratin 8 and 18. The cytokeratin dependent drug resistance (C-MDR) has been observed in two different cell types that were engineered to contain cytokeratin 8 and 18 expression. The cytokeratin monomers are known to self assemble into intermediate filament networks as shown by numerous basic studies. Experiments using transfected cell lines which are unable to assemble networks indicated that C-MDR does not depend upon the formation of an intermediate filament network. Selection of cytokeratin network defective tumor cells did not increase their sensitivity to chemotherapeutic agents. These data are interesting since it suggests that the C-MDR phenotype is not dependent upon the structural nature (i.e. network forming ability) of the cytokeratin. Our current working hypothesis is that the interaction of the damaging agent with cytokeratin may initiate signaling response(s) for cell survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hedley DW: Flow cytometric assays of anticancer drug resistance (review). Ann NY Acad Sci 67: 341–353, 1993

    Google Scholar 

  2. Tattersall MH: Mechanisms of treatment failure. Recent results Canc Res 127: 43–47, 1993

    Google Scholar 

  3. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR et al., e. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: 1253–1259, 1994

    Google Scholar 

  4. Clynes M: Cellular models for multiple drug resistance in cancer (review).In vitro cell. Dev Biol 29A (Part 1): 171–179, 1993

    Google Scholar 

  5. Deffie AM, Alam T, Senevirante C, Beenken S, Batra JK, Shea TC, Henner WD, Goldenberg GJ: Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and resistant p388 leukemia. Cancer Res 48: 3595–3602, 1988

    Google Scholar 

  6. Simon S, Roy D, Schindler M: Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci USA 91: 1128–1132, 1994

    Google Scholar 

  7. Dulhanty AM, Li M, Whitmore GF: Isolation of Chinese hamster ovary cell mutants deficient in excision repair and mitomycin C bioactivation. Cancer Res 49: 117–122, 1989

    Google Scholar 

  8. Dalton WS, Cress AE, Alberts DS, Trent JM: Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res 48: 1882–1888, 1988

    Google Scholar 

  9. Moll R: Molecular diversity of cytokeratins: significance for cell and tumor differentiation. Acta Histochem—Suppl 41: 117–127, 1991

    Google Scholar 

  10. Durr FE: Biologic and biochemical effects of mitoxantrone. Sem Oncol 11: 3–10, 1984

    Google Scholar 

  11. Dorr RT, Fritz WL: Cancer Chemotherapy Handbook, p. 785. New York: Elsevier Science Publishing Co., Inc., 1983

    Google Scholar 

  12. Gabor F, Wollman K, Theyer G, Haberl I, Hamilton C:In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells. Anti-cancer Res 14: 1943–1950, 1994

    Google Scholar 

  13. Haskell CM, Sullivan A: Comparative survival in tissue culture of normal and neoplastic human cells exposed to adriamycin. Cancer Res 34: 2991–2994, 1974

    Google Scholar 

  14. Scott CA, Westmacott D, Broadhurst MJ, Thomas GJ, Hall MJ: 9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures. Brit J Cancer 53: 595–600, 1986

    Google Scholar 

  15. Durr FE: Biologic and biochemical effects of mitoxantrone. Sem Oncol 11: 3–10, 1984

    Google Scholar 

  16. Cress AE: Modification of keratin by the chemotherapeutic drug mitoxantrone. Biochem Pharm 37: 3043–3046, 1988

    Google Scholar 

  17. Bauman PA: Interactions of mitoxantrone with cytokeratin in human and murine tumor cells: University of Arizona, 1993

  18. Marchuk D, McCrohon, Fuchs E: Remarkable conservation of structure among intermediate filament genes. Cell 39: 491–498, 1984

    Google Scholar 

  19. Steinert PM: Structure, function and dynamics of keratin intermediate filaments (review). J Invest Dermatol 100: 729–734, 1993

    Google Scholar 

  20. Coulombe PA: The cellular and molecular biology of keratins: beginning a new era. Curr Opin Cell Biol 5: 17–29, 1993

    Google Scholar 

  21. Klymkowsky MW, Bachant JB, Domingo A: Cell Motil. Cytoskel 14: 309–311, 1989

    Google Scholar 

  22. Nagle RB: Cytokeratin expression in carcinoma. Vol 2, p 387–410: Academic Press, 1994

  23. Bodenmuller H, Ofenloch-Hahnle B, Lane EB, dessauer A, Bottger V, Donie F: Lung cancer-associated keratin 19 fragments: development and biochemical characterisation of the new serum assay. Enzymun-Test CYFRA 21–1, Internat J Biol Markers 9: 75–81, 1994

    Google Scholar 

  24. Bynum WF, Contagion, 1st edition, p 494. Princeton: Princeton University Press, 1981

    Google Scholar 

  25. Bauman PA, Dalton WS, Anderson JM, Cress AE: Expression of cytokeratin confers multiple drug resistance. Proc Nat Acad Sci USA 91: 5311–5314, 1994

    Google Scholar 

  26. Anderson JM, Heindl LM, Bauman PA, Ludi CW, Dalton WS, Cress AE: Cytokeratin expression results in a drug-resistant phenotype to six different chemotherapeutic agents. Clin Cancer Res 2: 97–105, 1996

    Google Scholar 

  27. Brambilla E, Moro D, Gazzeri S, Brichon PY, Nagy-Mignotte H, Morel F, Jacrot M, Brambilla C: Cytotoxic chemotherapy induces cell differentiation in small-cell lung carcinoma. J Clin Oncol 9: 50–61, 1991

    Google Scholar 

  28. Oshima RG: Intermediate filament molecular biology. Curr Opin Cell Biol 4: 110–116, 1992

    Google Scholar 

  29. Lu X, Lane EB: Retrovirus-mediated transgenic keratin expression in cultured fibroblasts: specific domain functions in keratin stabilization and filament formation. Cell 62: 681–696, 1990

    Google Scholar 

  30. Kulesh DA, Cecena G, Darmon YM, Vasseur M, Oshima RG: Post-translational regulation of keratins: degradation of mouse and human keratins 18 and 8. Mol Cell Biol 9: 1553–1565, 1989

    Google Scholar 

  31. Nickoloff BJ, Turka LA: Keratinocytes: key immunocytes of the integument. Amer J Pathol 143: 325–331, 1993

    Google Scholar 

  32. Haskell CM, Sullivan A: Comparative survival in tissue culture of normal and neoplastic human cells exposed to adriamycin. Cancer Res 34: 2991–2994, 1974

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, The Arizona Cancer Center, University of Arizona, 85724, Tucson, AZ, USA

    Anne E. Cress & William S. Dalton

  2. Department of Medicine, The Arizona Cancer Center, University of Arizona, 85724, Tucson, AZ, USA

    Anne E. Cress & William S. Dalton

Authors
  1. Anne E. Cress
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William S. Dalton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cress, A.E., Dalton, W.S. Multiple drug resistance and intermediate filaments. Cancer Metast Rev 15, 499–506 (1996). https://doi.org/10.1007/BF00054015

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00054015

Key words

Search

Navigation